Skip to main content
TipRanks
Go Ultimate75% OFF

LEOCLAN Co. Ltd. (7681) AI Stock Analysis

0 Followers
JP:7681

LEOCLAN Co. Ltd.

(TSE/TYO:7681)

Select Model
Rating:69Neutral
Price Target:JPY 968.00â–²(12.04% Upside)
Action:reiterated
Date:11/18/26

The overall score of 69 is primarily driven by excellent cash flow generation, impressive revenue growth, and an attractive fundamental valuation. However, this optimism is notably limited by poor technical indicators and downward price trends, signaling caution for near-term momentum.

Positive Factors
Revenue GrowthThe return to approximately 15.9% revenue growth indicates renewed demand or business activity after a weaker period. If sustained, stronger sales can improve operating leverage, support reinvestment, and reinforce the company’s ability to grow earnings over the next several quarters.
Negative Factors
Very Thin Net MarginsA sub-1% net margin leaves little room to absorb cost increases, revenue volatility, or operating setbacks. Even with improved operating profitability, the limited final earnings cushion makes sustained profit growth fragile and increases sensitivity to modest changes in performance.

LEOCLAN Co. Ltd. (7681) vs. iShares MSCI Japan ETF (EWJ)

-30%-20%-10%0%10%20%30%JP:7681-6.29%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 5.12B
Dividend Yield
1.97%
Average Volume (3M)
1,504
Price to Earnings (P/E)
14.7
Beta (1Y)
-0.13
Revenue Growth
118.29%
EPS Growth
125.76%
Country
Japan
Employees
155
Sector
Healthcare
Sector Strength
51
Industry
Medical - Distribution

LEOCLAN Co. Ltd. Business Overview & Revenue Model

Company Description

LEOCLAN Co.,Ltd. operates as a medical equipment trading firm, addressing diverse needs across medical care, welfare, and general health sectors. Its operations are structured into three main divisions: Medical Total Solutions Business, Remote Image...

LEOCLAN Co. Ltd. Financial Statement Overview

Summary

Strong financial performance highlighted by massive revenue expansion and a robust rebound in cash flow, though slightly offset by structurally thin profit margins and elevated leverage.

Income Statement

82Very Positive

Balance Sheet

70Positive

Cash Flow

88Very Positive
Financial statement breakdown
BreakdownTTMSep 2026Sep 2025Sep 2024Sep 2023Sep 2022
Income Statement
Total Revenue40.47B46.91B21.49B19.80B26.63B29.77B
Gross Profit4.99B6.15B2.74B2.62B2.82B3.06B
EBITDA916.42M1.24B400.58M375.47M553.93M789.05M
Net Income115.68M346.69M152.78M136.06M271.31M437.05M
Balance Sheet
Total Assets22.30B22.73B10.91B10.66B14.75B13.52B
Cash, Cash Equivalents and Short-Term Investments8.78B6.45B4.78B5.57B5.54B5.48B
Total Debt4.90B4.66B7.19M12.57M5.67M99.82M
Total Liabilities16.28B16.65B5.09B4.93B9.02B7.98B
Stockholders Equity5.83B5.88B5.63B5.57B5.57B5.38B
Cash Flow
Free Cash Flow-116.70M1.03B-116.70M17.72M291.06M215.57M
Operating Cash Flow-86.65M1.66B-86.65M33.08M341.56M242.36M
Investing Cash Flow-619.82M-4.33B-619.82M100.75M-82.01M-49.96M
Financing Cash Flow-100.73M4.35B-100.73M-97.22M-202.31M-120.93M

LEOCLAN Co. Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price864.00

Price Trends

50DMA942.84Negative
100DMA943.50Negative
200DMA909.93Negative

Market Momentum

MACD-28.76Negative
RSI45.08Neutral
STOCH55.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7681, the sentiment is Negative. The current price of 864.00 is below the 20-day moving average (MA) of 888.90, below the 50-day MA of 942.84, and below the 200-day MA of 909.93, indicating a bearish trend. The MACD of -28.76 indicates Negative momentum. The RSI at 45.08 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7681.

LEOCLAN Co. Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:7681 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:7681JP:768169NeutralJPY 5.12B14.74―1.97%118.29%125.76%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:7776JP:777644NeutralJPY 5.63B-4.61――-49.43%-3.77%
JP:4978JP:497842NeutralJPY 11.22B-24.14――-8.23%-48.10%
JP:7774JP:777442NeutralJPY 25.18B-70.06――17.05%10.47%
JP:3750JP:375040UnderperformJPY 6.78B-13.82――101.85%73.33%
JP:4599JP:459939UnderperformJPY 7.65B-4.11―――4.85%

* Healthcare Sector Average

Performance Comparison

-50%0%50%JP:7681JP:3750JP:4599JP:4978JP:7774JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:7681 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:7681LEOCLAN Co. Ltd.864.00-44.28-4.87%
JP:3750Cytori Cell Research Institute, Inc.759.00-55.00-6.76%
JP:4599StemRIM Inc.122.00-157.00-56.27%
JP:4978ReproCELL Inc.105.00-50.00-32.26%
JP:7774Japan Tissue Engineering Co., Ltd.620.00134.0027.57%
JP:7776CellSeed Inc.142.00-152.00-51.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 18, 2026